Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
China
Research
China approved the first solid tumor CAR-T. Will the US follow?
While satri-cel may soon broaden its reach to more Chinese patients, the game-changing therapy is unlikely to hit the American market anytime soon.
Darren Incorvaia
Jun 30, 2026 10:00am
Fierce Pharma
Fosun Pharma plots global push, fueled by Alzheimer’s deals
Jun 25, 2026 7:00pm
Eli Lilly reunites with Abbisko in $1.9B, multitarget R&D pact
Jun 24, 2026 7:47am
Serapha takes flight with $230M, gene-editing prospect from China
Jun 23, 2026 1:55pm
Fierce Pharma
Obesity meds, China drive $2T in projected 2032 drug sales: report
Jun 23, 2026 9:00am
Corxel touts ‘competitive’ ph. 2 results for oral GLP-1 asset
Jun 23, 2026 8:00am